Post hoc analysis of two phase 3 trials in adults/adolescents with moderate-to-severe atopic dermatitis: at week 16, significantly more patients on lebrikizumab (n=564) than placebo (n=287) reached absolute EASI ≤7, ≤5, ≤3 and ≤1, across baseline severities.
Secondary analysisn = 851
Thaçi et al. Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials